Welcure Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 116.00 Cr
as on 04-10-2024
- Paid Up Capital ₹ 13.44 Cr
as on 04-10-2024
- Company Age 28 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 22.08 Cr
as on 04-10-2024
- Revenue 125.85%
(FY 2023)
- Profit 331.41%
(FY 2023)
- Ebitda -660.67%
(FY 2023)
- Net Worth 1529.22%
(FY 2023)
- Total Assets 1479.10%
(FY 2023)
About Welcure Drugs And Pharmaceuticals
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524661.
The Company is engaged in the Real Estate Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 116.00 Cr and a paid-up capital of Rs 13.44 Cr.
The company has closed loans amounting to ₹22.08 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Welcure Drugs And Pharmaceuticals Limited India are Altaf Shah as CFO and Manowar Ali as Company Secretary. Ashish Abbi, Suraj Solanki, Altaf Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
L24232DL1996PLC227773
- Company No.
227773
- Stock Symbol
BSE : 524661
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Aug 1996
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Welcure Drugs And Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Altaf Shah | CFO | 29-Feb-2024 | Current |
| Manowar Ali | Company Secretary | 22-Oct-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Abbi  | Director | 22-May-2024 | Current |
| Suraj Solanki | Additional Director | Current | |
| Deepika Iyer | Director | 29-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Welcure Drugs And Pharmaceuticals.
Welcure Drugs And Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 125.85% increase. The company also saw a substantial improvement in profitability, with a 331.41% increase in profit. The company's net worth Soared by an impressive increase of 1529.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Welcure Drugs And Pharmaceuticals?
In 2022, Welcure Drugs And Pharmaceuticals had a promoter holding of 14.12% and a public holding of 85.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 28 Sep 2004 | ₹3.68 Cr | Satisfied |
State Bank Of India Creation Date: 30 Aug 2004 | ₹18.40 Cr | Satisfied |
How Many Employees Work at Welcure Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with Welcure Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Welcure Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Welcure Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
